Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mereo BioPharma
With
Novartis
Age
30–65
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Males who meet the criteria of obese, hypogonadotropic hypogonadism defined as:
* Patients with a Body Mass Index (BMI) ≥ 30 kg/m2
* Patients with a morning serum total testosterone level \< 300 ng/dL on at least two separate occasions during the Screening and/or Baseline periods.
* Patients with inappropriately low gonadotropins at screening given the low testosterone:
Luteinizing hormone (LH) ≤ ULN
Follicle stimulating hormone (FSH) ≤ ULN
Estradiol within or above the normal range (defined as ≥ LLN of the approved assay)
* Normal hypothalamic/pituitary function, including:
Prolactin: within the normal range
Thyroid stimulating hormone (TSH): within the normal range
Ferritin: within the normal range
Patients agree to use a barrier method of contraception (e.g., condom), for the duration of the study and for at least 3 months following their Study Completion visit to prevent BGS649 exposure to their partners.
You may not be if
Patients with hypogonadism, not related to obesity or as a result of other underlying issues
Patients with significant major organ class illness (e.g. kidney or liver disease).
